# Contents

Contributors list  vii  
Editor biography  ix  

1  **Introduction and disease overview**  1  
References  9  

2  **Incretin hormones as a target for therapy**  11  
Incretin hormone physiology  11  
The incretin-producing cell  11  
GIP and GLP-1 action  13  
Measurement of the incretin hormones  17  
Incretin action in healthy individuals  18  
Incretin action in patients with type 2 diabetes  18  
Therapeutics application  21  
References  26  

3  **Glucagon-like peptide receptor agonists**  31  
Introduction  31  
GLP-1 receptor agonists  32  
Extrapancreatic effects GLP-1 receptor agonists  37  
Pancreatic safety  39  
Perspectives  40  
References  41  

4  **Dipeptidyl peptidase-4 inhibitors**  45  
Introduction  45  
Pharmacokinetics and pharmacodynamics  45  
Efficacy  47  
Combination therapy  48  
Use in specific patient populations  50  
Safety  52
## Conclusions  57  
References  58

### 5  Global position and recommendations for use  61

- **Introduction**  61
- American Association of Clinical Endocrinologists/American College of Endocrinology  61
- American Diabetes Association /European Association for the Study of Diabetes 65
- International Diabetes Federation  65
- National Institute of Health and Care Excellence  67
- Using incretin-based therapies in clinical practice  70
- Availability and licences  71
- References  74

### 6  Future and emerging therapies  77

- **Introduction**  77
- Once-weekly agents under investigation  77
- Subcutaneous implants  81
- Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors  84
- Other indications for incretin therapies  85
- DPP-4 inhibitors  86
- References  89
Handbook of Incretin-based Therapies in Type 2 Diabetes
Gough, S. (Ed.)
2016, IX, 92 p. 20 illus., 16 illus. in color., Softcover
ISBN: 978-3-319-08981-2